Alisha Lussiez1, Samantha J Rivard1, Kamren Hollingsworth2, Sherif R Z Abdel-Misih3, Philip S Bauer4, Katherine A Hrebinko5, Glen C Balch6,7, Lillias H Maguire8. 1. Department of Surgery, University of Michigan, Ann Arbor, Michigan. 2. Section of Colon & Rectal Surgery, Division of General Surgery, Vanderbilt University Medical Center, Nashville, Tennessee. 3. Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, Ohio. 4. Section of Colon & Rectal Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Missouri. 5. Division of Colon and Rectal Surgery, Department of Surgery, University of Pittsburg Medical Center, Pittsburgh, Pennsylvania. 6. Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. 7. Division of Colon & Rectal Surgery, Department of Surgery, Emory University, Atlanta, Georgia. 8. Division of Colorectal Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Preoperative staging of clinical stage I rectal cancer can fail to diagnose T3 or nodal disease. Adjuvant treatment of these upstaged patients remains controversial. Objective: The objective was to identify predictors of clinical stage I rectal cancer upstaging and quantify rates of local and systemic recurrence. Design: This was a retrospective cohort study. Settings: The study was conducted using the data from the United States Rectal Cancer Consortium, a registry of 1,881 rectal cancer resections performed at six academic medical centers. Patients: There were a total of 94 clinical stage I rectal cancer patients who underwent proctectomy without preoperative therapy. Main Outcome Measures: The primary measures were incidence of pathologic upstaging, recurrence (local and systemic), and overall survival. Results: Among 94 clinical stage I patients who underwent proctectomy without preoperative therapy, 23 (24.5%) were upstaged by surgical pathology. There were 6 pT3N0 patients, 8 pT1-2N+, and 9 pT3N+. There were no significant differences in demographic or clinical characteristics between upstaged and non-upstaged patients. Of the 6 patients who were upstaged to T3N0 disease, none received adjuvant therapy and none recurred. Of the 17 patients who were upstaged to N+ disease, 14 (82%) received adjuvant chemotherapy and 6 (35%) received adjuvant chemoradiation. None developed a local recurrence, but 4 (24%) developed systemic recurrence, and 2 (12%) died of disease over a mean of 36 months follow-up. Among the 9 pT3N+ patients, the systemic recurrence rate was 33%, despite 8 of 9 patients receiving adjuvant fluorouracil, leucovorin, and oxaliplatin. Limitations: Small sample size hinders ability to draw significant conclusions. Conclusions: One in four patients with stage I rectal cancer had unrecognized T3 or nodal disease found on operative pathology. Occult nodal disease was associated with worse outcomes, despite receiving adjuvant therapy. Systemic recurrence was more common than local recurrence. See Video Abstract at http://links.lww.com/DCR/B885. (C) 2022 The American Society of Colon and Rectal Surgeons.
BACKGROUND: Preoperative staging of clinical stage I rectal cancer can fail to diagnose T3 or nodal disease. Adjuvant treatment of these upstaged patients remains controversial. Objective: The objective was to identify predictors of clinical stage I rectal cancer upstaging and quantify rates of local and systemic recurrence. Design: This was a retrospective cohort study. Settings: The study was conducted using the data from the United States Rectal Cancer Consortium, a registry of 1,881 rectal cancer resections performed at six academic medical centers. Patients: There were a total of 94 clinical stage I rectal cancer patients who underwent proctectomy without preoperative therapy. Main Outcome Measures: The primary measures were incidence of pathologic upstaging, recurrence (local and systemic), and overall survival. Results: Among 94 clinical stage I patients who underwent proctectomy without preoperative therapy, 23 (24.5%) were upstaged by surgical pathology. There were 6 pT3N0 patients, 8 pT1-2N+, and 9 pT3N+. There were no significant differences in demographic or clinical characteristics between upstaged and non-upstaged patients. Of the 6 patients who were upstaged to T3N0 disease, none received adjuvant therapy and none recurred. Of the 17 patients who were upstaged to N+ disease, 14 (82%) received adjuvant chemotherapy and 6 (35%) received adjuvant chemoradiation. None developed a local recurrence, but 4 (24%) developed systemic recurrence, and 2 (12%) died of disease over a mean of 36 months follow-up. Among the 9 pT3N+ patients, the systemic recurrence rate was 33%, despite 8 of 9 patients receiving adjuvant fluorouracil, leucovorin, and oxaliplatin. Limitations: Small sample size hinders ability to draw significant conclusions. Conclusions: One in four patients with stage I rectal cancer had unrecognized T3 or nodal disease found on operative pathology. Occult nodal disease was associated with worse outcomes, despite receiving adjuvant therapy. Systemic recurrence was more common than local recurrence. See Video Abstract at http://links.lww.com/DCR/B885. (C) 2022 The American Society of Colon and Rectal Surgeons.
Authors: Paul F Engstrom; Juan Pablo Arnoletti; Al B Benson; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Anne Covey; Raza A Dilawari; Dayna S Early; Peter C Enzinger; Marwan G Fakih; James Fleshman; Charles Fuchs; Jean L Grem; Krystyna Kiel; James A Knol; Lucille A Leong; Edward Lin; Mary F Mulcahy; Sujata Rao; David P Ryan; Leonard Saltz; David Shibata; John M Skibber; Constantinos Sofocleous; James Thomas; Alan P Venook; Christopher Willett Journal: J Natl Compr Canc Netw Date: 2009-09 Impact factor: 11.908
Authors: Ahmed Dehal; Amanda N Graff-Baker; Brooke Vuong; Daniel Nelson; Shu-Ching Chang; Melanie Goldfarb; Anton J Bilchik Journal: Am Surg Date: 2018-10-01 Impact factor: 0.688
Authors: Nouf Akeel; Nan Lan; Luca Stocchi; Meagan M Costedio; David W Dietz; Emre Gorgun; Matthew F Kalady; Georgios Karagkounis; Hermann Kessler; Feza H Remzi Journal: J Gastrointest Surg Date: 2016-10-27 Impact factor: 3.452
Authors: Luc A Heijnen; Doenja M J Lambregts; Dipanjali Mondal; Milou H Martens; Robert G Riedl; Geerard L Beets; Regina G H Beets-Tan Journal: Eur Radiol Date: 2013-07-03 Impact factor: 5.315
Authors: N Wolmark; H S Wieand; D M Hyams; L Colangelo; N V Dimitrov; E H Romond; M Wexler; D Prager; A B Cruz; P H Gordon; N J Petrelli; M Deutsch; E Mamounas; D L Wickerham; E R Fisher; H Rockette; B Fisher Journal: J Natl Cancer Inst Date: 2000-03-01 Impact factor: 13.506
Authors: Praveen Polamraju; Waqar Haque; Vivek Verma; Lee Wiederhold; Sandra Hatch; E Brian Butler; Bin S Teh Journal: Clin Colorectal Cancer Date: 2018-04-21 Impact factor: 4.481
Authors: Byung Mo Kang; Jeong-Heum Baek; Sun Jin Park; Seong Kyu Baek; Ki-Jae Park; Hong-Jo Choi; Byung-Noe Bae; Sun Keun Choi; Kap Tae Kim; Jin-Su Kim; Suk-Hwan Lee Journal: Ann Coloproctol Date: 2018-06-30